RXST RxSight, Inc.
Ophthalmic Goods · Nasdaq · SEC CIK 1111485 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-14.3%
TTM net income YoY-49.3%
TTM EPS YoY-46.6%
Revenue 3-yr CAGR16.7%
Net income 3-yr CAGR—
Margins
Gross margin76.1%
Operating margin-50.4%
Net margin-43.8%
FCF margin15.3%
EBITDA margin-47.5%
Returns
ROE-20.1%
ROA-16.4%
ROIC (approx.)-22.4%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets25.1%
Debt / equity0.00x
Current ratio4.20x
Interest coverage-4,389.57x
Cash quality & payout
Operating cash flow / net income-0.44x
Accruals ratio-23.7%
Payout ratio—
Capex / revenue4.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $134.48M | $139.93M | $89.08M | $49.01M | $22.59M |
| Cost of revenue | $31.47M | $40.98M | $35.31M | $27.68M | $18.08M |
| Gross profit | $103.01M | $98.94M | $53.77M | $21.33M | $4.52M |
| R&D expense | $38.55M | $34.37M | $29.05M | $25.98M | $24.50M |
| SG&A expense | $112.65M | $101.43M | $74.80M | $58.66M | $32.80M |
| Operating income | -$48.19M | -$36.86M | -$50.09M | -$63.32M | -$52.79M |
| Interest expense | $19,000 | $21,000 | $3.31M | $4.95M | $3.68M |
| Pretax income | -$38.88M | -$27.41M | -$48.59M | -$66.75M | -$48.68M |
| Income tax | $66,000 | $50,000 | $20,000 | $9,000 | $8,000 |
| Net income | -$38.94M | -$27.45M | -$48.61M | -$66.76M | -$48.69M |
| EBITDA | -$44.92M | -$33.28M | -$46.01M | -$59.43M | -$48.81M |
| EPS (basic) | -0.95 | -0.71 | -1.41 | -2.41 | -3.57 |
| EPS (diluted) | -0.95 | -0.71 | -1.41 | -2.41 | -3.57 |
| Weighted avg. shares (diluted) | 40.85M | 38.87M | 34.46M | 27.66M | 13.63M |
| Balance sheet | |||||
| Cash & equivalents | $19.95M | $17.46M | $10.40M | $12.60M | $25.17M |
| Short-term investments | $208.18M | $220.52M | $117.49M | $93.97M | $134.97M |
| Receivables | $23.38M | $30.05M | $20.28M | $10.96M | $4.86M |
| Inventory | $31.56M | $22.01M | $17.42M | $14.84M | $8.03M |
| Current assets | $287.46M | $293.82M | $168.41M | $134.56M | $176.29M |
| PP&E, net | $13.06M | $12.41M | $10.84M | $10.14M | $11.22M |
| Total assets | $311.81M | $318.56M | $182.55M | $150.16M | $192.72M |
| Current liabilities | $26.25M | $25.88M | $20.90M | $17.24M | $11.08M |
| Long-term debt | — | — | $0 | $40.17M | $39.76M |
| Total debt | — | — | $0 | $40.17M | $39.76M |
| Total liabilities | $36.13M | $37.33M | $22.19M | $60.26M | $54.48M |
| Shareholders' equity | $275.68M | $281.24M | $160.36M | $89.90M | $138.24M |
| Net debt | — | — | -$10.40M | $27.57M | $14.59M |
| Shares outstanding | 41.24M | 40.43M | 36.14M | 28.27M | 27.37M |
| Cash flow statement | |||||
| Operating cash flow | -$15.51M | -$16.95M | -$41.59M | -$58.85M | -$44.71M |
| Capital expenditure | $3.83M | $5.44M | $4.81M | $2.39M | $1.94M |
| Free cash flow | -$19.34M | -$22.39M | -$46.41M | -$61.24M | -$46.65M |
| Investing cash flow | $16.89M | -$99.31M | -$22.13M | $39.95M | -$81.91M |
| Financing cash flow | $1.86M | $123.32M | $61.52M | $6.33M | $137.34M |
| Depreciation & amortization | $3.27M | $3.58M | $4.08M | $3.88M | $3.98M |
| Stock-based compensation | $31.61M | $24.64M | $15.75M | $11.40M | $7.58M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.